{'52WeekChange': 0.6074327,
 'SandP52WeekChange': 0.0644362,
 'address1': 'One MedImmune Way',
 'address2': 'First Floor Area Two',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 37.62,
 'askSize': 1100,
 'averageDailyVolume10Day': 193312,
 'averageVolume': 416320,
 'averageVolume10days': 193312,
 'beta': None,
 'beta3Year': None,
 'bid': 37.54,
 'bidSize': 1100,
 'bookValue': -297.665,
 'category': None,
 'circulatingSupply': None,
 'city': 'Gaithersburg',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 38.03,
 'dayLow': 36.22,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -14.596,
 'enterpriseToRevenue': 32.084,
 'enterpriseValue': 1604198400,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 44.724857,
 'fiftyTwoWeekHigh': 70.66,
 'fiftyTwoWeekLow': 18.2,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 16779132,
 'forwardEps': -2.89,
 'forwardPE': -13.0207615,
 'fromCurrency': None,
 'fullTimeEmployees': 147,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.56896996,
 'heldPercentInstitutions': 0.37931,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/vielabio.com',
 'longBusinessSummary': 'Viela Bio, Inc., a clinical-stage biotechnology '
                        'company, engages in the research and development of '
                        'treatments for severe inflammation and autoimmune '
                        "diseases in the United States. The company's lead "
                        'product candidate is inebilizumab, a humanized '
                        'monoclonal antibody for neuromyelitis optica spectrum '
                        'disorder, kidney transplant desensitization, '
                        'myasthenia gravis, and IgG4-related diseases. It is '
                        'also developing VIB4920 for kidney transplantation '
                        "rejection and sj√∂gren's syndrome; and VIB7734 for "
                        'cutaneous lupus erythematosus. Viela Bio, Inc. has a '
                        'strategic collaboration with Mitsubishi Tanabe Pharma '
                        'Corporation to develop and commercialize inebilizumab '
                        'for autoimmune diseases in Japan, Thailand, South '
                        'Korea, Indonesia, Vietnam, Malaysia, the Philippines, '
                        'Singapore, and Taiwan. The company was founded in '
                        '2017 and is headquartered in Gaithersburg, Maryland.',
 'longName': 'Viela Bio, Inc.',
 'market': 'us_market',
 'marketCap': 1919028480,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_554421825',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -106230000,
 'nextFiscalYearEnd': 1640908800,
 'open': 37.72,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '240 558 0038',
 'previousClose': 37.95,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 38.38057,
 'profitMargins': -2.1246002,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 38.03,
 'regularMarketDayLow': 36.22,
 'regularMarketOpen': 37.72,
 'regularMarketPreviousClose': 37.95,
 'regularMarketPrice': 37.72,
 'regularMarketVolume': 116184,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 50997300,
 'sharesPercentSharesOut': 0.0482,
 'sharesShort': 2456836,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1781548,
 'shortName': 'Viela Bio, Inc.',
 'shortPercentOfFloat': 0.120299995,
 'shortRatio': 3.57,
 'startDate': None,
 'state': 'MD',
 'strikePrice': None,
 'symbol': 'VIE',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -103.073,
 'twoHundredDayAverage': 42.353527,
 'volume': 116184,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.vielabio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '20878'}